Jeanine M. Walenga - Concepedia

Author

Jeanine M. Walenga

Also Known As

Hikari Watanabe, J Breddin, J M Walen-ga, J M Walenga, J Martinoli, J Walenga, J. M. WALENGA, J. M. Walenga, J. Walenga, J.M Walenga

570

Publications

Citations

H-Index

148

Concepts

All Affiliations

Loyola University Medical Center Loyola University Chicago

About

Jeanine M. Walenga is an author at Loyola University Medical Center specializing in thrombosis, medicine, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	84	3K
2	Public Health	8	8	533
3	Health Sciences	5	5	144
4	Engineering	3	3	56
5	Natural Sciences	3	3	92

Jeanine M. Walenga

122

Publications

Citations

H-Index

Page 1

	Year	Citations
Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia Bruce Lewis, Diane E. Wallis, Scott D. Berkowitz, Circulation	2001	655
Prevention And Treatment Of Venous Thromboembolism : International Consensus Statement Andrew Nicolaides, Jawed Fareed, A.K. Kakkar, International Journal of Angiology PharmacotherapyThrombosisVenous ThrombosisVenous Disease TreatmentConcise Account	2013	194
Prevention and Treatment of Venous Thromboembolism Aliki Nicolaides, Jawed Fareed, A.K. Kakkar, Clinical and Applied Thrombosis/Hemostasis Pulmonary EmbolismThrombosisVenous ThrombosisCardiovascular DiseaseMedicine	2013	185
The Society of Thoracic Surgeons Practice Guideline Series: Aspirin and Other Antiplatelet Agents During Operative Coronary Revascularization (Executive Summary)* Victor A. Ferraris, Suellen P. Ferraris, David J. Moliterno, The Annals of Thoracic Surgery Percutaneous Coronary InterventionThrombosisCardiothoracic SurgeryCardiovascular DiseaseCoronary Artery Disease	2005	154
Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands Narayanam V. Rao, Brian Argyle, Xiaoyu Xu, American Journal of Physiology-Cell Physiology ImmunologyHeparin Disrupt Mac-1ImmunotherapyInflammationThrombosis	2010	132
Oligosaccharide mapping of low-molecular-weight heparins: structure and activity differences Robert J. Linhardt, Duraikkannu Loganathan, Ali Al‐Hakim, Journal of Medicinal Chemistry	1990	109
New Anticoagulants for the Cardiovascular Patient Jeanine M. Walenga, Jawed Fareed, Rodger L. Bick, Clinical and Applied Thrombosis/Hemostasis Blood PreservationPharmacotherapyComprehensive Proto ColThrombosisHematology	1995	98
Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges Jeanine M. Walenga, Maurice Petitou, J C Lormeau, Thrombosis Research ThrombopoiesisThrombosisBlood PlateletMedicineHematology	1987	92
Interleukin-2 and interleukin-6 in relation to burn wound size in the acute phase of thermal injury. Areta Kowal-Vern, Jeanine M. Walenga, Debra Hoppensteadt, PubMed	1994	91
Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia Jeanine M. Walenga, Sarfraz Ahmad, Debra Hoppensteadt, Thrombosis Research ThrombopoiesisThrombosisArgatroban TherapyAutoimmune DiseaseBlood Platelet	2002	87

Page 1